Show simple item record

dc.contributor.authorLose, Felicityen_US
dc.contributor.authorG. Lawrence, Mitchellen_US
dc.contributor.authorSrinivasan, Srilakshmien_US
dc.contributor.authorO'Mara, Tracyen_US
dc.contributor.authorMarquart, Louiseen_US
dc.contributor.authorChambers, Suzanneen_US
dc.contributor.authorA. Gardiner, Roberten_US
dc.contributor.authorAitken, Joanneen_US
dc.contributor.authorB. Spurdle, Amandaen_US
dc.contributor.authorBatra, Jyotsnaen_US
dc.contributor.authorA. Clements, Judithen_US
dc.contributor.authorProstate Cancer BioResource, The Australianen_US
dc.date.accessioned2017-04-24T10:14:08Z
dc.date.available2017-04-24T10:14:08Z
dc.date.issued2012en_US
dc.identifier.issn1431-6730en_US
dc.identifier.doi10.1515/hsz-2011-0268en_US
dc.identifier.urihttp://hdl.handle.net/10072/47551
dc.description.abstractKallikrein 14 (KLK14) has been proposed as a useful prognostic marker in prostate cancer, with expression reported to be associated with tumour characteristics such as higher stage and Gleason score. KLK14 tumour expression has also shown the potential to predict prostate cancer patients at risk of disease recurrence after radical prostatectomy. The KLKs are a remarkably hormone-responsive family of genes, although detailed studies of androgen regulation of KLK14 in prostate cancer have not been undertaken to date. Using in vitro studies, we have demonstrated that unlike any other prostatic KLK genes that are strictly androgen responsive, KLK14 is more broadly expressed and inversely androgen regulated in prostate cancer cells. Given these results and evidence that KLK14 may play a role in prostate cancer prognosis, we also investigated whether common genetic variants in the KLK14 locus are associated with risk and/or aggressiveness of prostate cancer in approximately 1200 prostate cancer cases and 1300 male controls. Of 41 single nucleotide polymorphisms assessed, three were associated with higher Gleason score ( = 7): rs17728459 and rs4802765, both located upstream of KLK14 , and rs35287116, which encodes a p.Gln33Arg substitution in the KLK14 signal peptide region. Our findings provide further support for KLK14 as a marker of prognosis in prostate cancer.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_US
dc.format.extent544714 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglishen_US
dc.language.isoen_US
dc.publisherWalter de Gruyteren_US
dc.publisher.placeGermanyen_US
dc.relation.ispartofstudentpublicationNen_US
dc.relation.ispartofpagefrom403en_US
dc.relation.ispartofpageto412en_US
dc.relation.ispartofissue5en_US
dc.relation.ispartofjournalBiological Chemistryen_US
dc.relation.ispartofvolume393en_US
dc.rights.retentionYen_US
dc.subject.fieldofresearchPsychology not elsewhere classifieden_US
dc.subject.fieldofresearchcode170199en_US
dc.titleThe kallikrein 14 gene is down-regulated by androgen receptor signalling and harbours genetic variation that is associated with prostate tumour aggressivenessen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.rights.copyrightCopyright 2012 Walter de Gruyter & Co. KG Publishers. The attached file is reproduced here in accordance with the copyright policy of the publisher. Please refer to the journal's website for access to the definitive, published version.en_US
gro.date.issued2015-04-10T00:52:24Z
gro.hasfulltextFull Text


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record